- The BCG vaccine, primarily used for tuberculosis (TB) prevention and certain bladder cancer treatments, remains a cornerstone of immunization programs in developing countries and select clinical applications in developed regions due to its immunotherapeutic and preventive benefits
- Rising global TB prevalence, intensified public health campaigns, and increasing awareness of neonatal immunization have significantly elevated demand for BCG vaccines, particularly in Asia, Africa, and Latin America where TB remains endemic
- Asia-Pacific dominated the BCG vaccine market with the largest revenue share of 49.1% in 2024, fueled by national immunization mandates, high birth rates, and extensive vaccine distribution infrastructure, with India and China representing major consumption hubs supported by public-private healthcare collaborations
- The Middle East & Africa is projected to be the fastest growing region during the forecast period, driven by expanding healthcare access, increased government focus on TB eradication, and international funding support.
- Tuberculosis segment dominated the Bacillus Calmette-Guerin (BCG) vaccine market with a market share of 72.9% in 2024, driven by its widespread inclusion in national immunization programs and critical role in preventing severe TB forms in children
